Clover Health Investments (CLOV) CEO Wai Sells $111K of Stock
Key Points
- Conrad Wai, CEO of Counterpart Health at Clover Health Investments, Corp. (NasdaqGS: CLOV), sold 23,627 shares on October 15, 2026, at a price of $4.68 per share, totaling $110,574.36.
- After the trade, Conrad Wai holds 1,042,072 $CLOV shares, down 2.22% from before the trade.
- Institutional investors like Nuveen, LLC and PNC Financial Services Group adjusted their holdings in the healthcare provider ahead of upcoming earnings.
- Clover Health operates Medicare Advantage plans and the Clover Assistant software platform for physicians, with its next earnings report scheduled for November 4, 2026.
Since the trade, $CLOV is down 5.1% to date (from the $4.68 close on Oct 15, 2026).
Get Clover Health Investments, Corp. text alerts
We text you when insiders, Congress, analysts or big funds move on $CLOV.
By entering your mobile number and tapping the sign-up button, you provide express written consent to receive recurring automated text messages from TradeTexts at that number, including stock alerts about SEC filings, insider and congress trades, analyst ratings, hedge fund moves, and earnings results. Consent is not a condition of any purchase. Message frequency varies. Messages are not investment advice. Message and data rates may apply. Reply HELP for help and STOP to opt out at any time. See our Terms and Privacy Policy.
Not investment advice. TradeTexts is not a registered investment adviser, and this automated Clover Health Investments, Corp. alert may contain errors. Disclosures
Conrad Wai, CEO of Counterpart Health at Clover Health Investments, Corp. (NasdaqGS: CLOV), sold 23,627 shares of the company on October 15, 2026. According to a Form 4 filed with the Securities and Exchange Commission, the transaction was executed at a price of $4.68 per share, bringing the total value of the sale to $110,574.36.
CLOV
Clover Health Investments, Corp.
Inside Conrad Wai's Clover Health Trade
The stock transaction was carried out under a pre-arranged Rule 10b5-1 trading plan. Following the sale, Wai directly owns 1,042,072 shares of Clover Health, marking a reduction of about 2.22% in his personal holdings. The stock closed at $4.68 on the day of the transaction.
Other Institutional Activity in Clover Health
Large financial institutions have actively managed their stakes in the healthcare company. Nuveen, LLC grew its holdings by 5,356,158 shares, ending with 6,291,699 shares worth about $27,935,143. Meanwhile, PNC Financial Services Group, Inc. reduced its position, dropping 200,251 shares to end with 3,563,874 shares valued at roughly $15,823,600.
Clover Health Investments, Corp. Stock Down 7.3%
Shares recently traded around $4.44 as of October 19, 2026, down about 5.1% since the insider sale. The healthcare stock trades above its 200-day moving average but sits below its 52-week high of $5.59.
Recent Earnings
For trailing twelve months, Clover Health reported $2.48 billion in revenue alongside an EPS of -$0.05. The company is set to release its next financial results on November 4, 2026.
Insider Buying and Selling at Clover Health Investments, Corp.
Earlier insider activity included planned sales by executives such as Jamie Reynoso and Karen Soares in mid-June 2026.
Analysts Set New Price Targets
Wall Street firms maintain varied stances on the stock, with Canaccord Genuity holding a Buy rating and a $5.50 price target.
About Clover Health
Based in Wilmington, Delaware, Clover Health Investments operates Medicare Advantage healthcare plans. The company also develops software tools designed to help physicians track and manage chronic illnesses.
Bottom Line
Investors will watch the upcoming earnings report on November 4, 2026, for further financial updates from the company.
Related Filing Alerts
Source: Conrad Wai's Form 4 filing on $CLOV (Oct 15, 2026). Written by software, not financial advice. How we make alerts